Graphical Abstract


Cancer cell lines predict drug response

Large-scale study could increase success rate of developing personalised cancer treatments

Research published in Cell has shown that patient-derived cancer cell lines harbour most of the same genetic changes found in patients' tumours, and could be used to learn how tumours are likely to respond to new drugs, increasing the success rate for developing new personalised cancer treatments.

David Tamborero and Núria López-Bigas, members of the Biomedical Genomics group of GRIB (UPF-IMIM) have participated on this international study led by scientists from the Wellcome Trust Sanger Institute, the European Bioinformatics Institute (EMBL-EBI) and the Netherlands Cancer Institute, discovering a strong link between many mutations in patient cancer samples, and the sensitivity to particular drugs. This could advance personalised cancer medicine by leading to results that help doctors predict the best available drugs, or the most suitable clinical trials for each individual patient.

In the first systematic, large-scale study to combine molecular data from patients, laboratory cancer cell lines and drug sensitivity, David Tamborero says: "one of the main difficulties of the study was to interpret the large amount of genomic alterations observed in the tumor cells', and continue: "our task was to identify the mutations that are important for the development of each of the cancers in order to associate them with the observed drug responses".

Click here to read the full Press Release of the Wellcome Trust Sanger Institute. 

More information


"El coll d'ampolla és ara en la interpretació de dades"

La gran quantitat de dades generades per la biomedicina ha donat peu, en els darrers anys, a una nova branca de científics: els bioinformàtics. En aquest camp excel·leix Núria López-Bigas, que ha estat distingida amb el premi Fundació Sabadell a la investigació biomèdica. Rebrà el guardó el dia 12 a Barcelona.

Veure entrevista a Núria López Bigas, investigadora ICREA del GRIB a El Punt avui clicant aquí.

More information


BIB launches its website to boost visibility of catalan bioinformatic potential

Bioinformatics Barcelona Association (BIB) launches its website, which aims to be a reference in the bioinformatic sector at national and international level, and to become the platform for communication and interaction among BIB's partners. Through this website, the association has enhanced its digital presence to become a meeting-point facilitator of initiatives and a think tank for the bioinformatic community.

The portal contains sections on the BIB partners and their research groups in the bioinformatic field, and on education and training, job offers and internships, news, activities and news clipping, as well as a section with specific information on the association itself. Ferran Sanz, Director of GRIB is the Vice-President of the Association's Board of directors.

More information



A new energy source within the cells

In a paper published in Science, researchers at the Centre for Genomic Regulation (CRG) led by group leader Miguel Beato in collaboration with Baldo Oliva and Jaume Bonet, head and postdoctoral researcher respectively of the Structural Bioinformatics group of GRIB (IMIM-UPF) and researchers of the IRB in Barcelona and the URV in Tarragona have described for the first time a new pathway generating energy within the cell nucleus for remodeling chromatin and reprogramming gene expression. They have also identified the function of enzymes involved at every step of this process and how they are activated in response to stress signals. Their results, will help in understanding the mechanisms underlying chromatin remodelling, its relationship with DNA damage and, by extension, with cancer. 

Exceptional situations call for extraordinary measures. When cells need to cope with a global reprogramming of gene expression they require a lot of energy in the nucleus. In these situations the cells block their mitochondrial and cytosolic ATP production to be focused on the main task in the nucleus," says Miguel Beato, principal investigator of this paper. 

Article reference: Wright R, Lioutas A, Le Dily F, Soronellas D, Pohl A, Bonet J, Nacht AS, Samino S, Puchades Carrasco L, Font-Mateu J, Vicent GP, Wierer M, Trabado MA, Schelhorn C, Carolis C, Macias MJ, Yanes O, Oliva B, Beato M. ADP-ribose-derived nuclear ATP synthesis by NUDIX5 is required for chromatin remodeling. Science, 352 (6290), 1221-1225. doi: 10.1126/ science. aad9335

More information


European project eTOX launches a new video

The video presents the 2nd  hackathon event held at PRBB and gives an insight into the eTOX project.

The eTOX project aims to develop a drug safety database from the pharmaceutical industry legacy toxicology reports and public toxicology data, innovative in silico strategies and novel software tools to better predict the toxicological profiles of small molecules in early stages of the drug development pipeline. The eTOX project is funded by the IMI and coordinated by the GRIB (IMIM-UPF).

More information


Congratulations to Núria López-Bigas for the XI Banco Sabadell Foundation Award for Biomedical Research

The Jury of the Award for Biomedical Research of the Banco Sabadell Foundation decided to give this prize to Núria López-Bigas, leader of the Biomedical Genomics group of GRIB (UPF-IMIM), for her contribution to the development of new bioinformatics methods to study cancer genomes. Her work opens up new avenues for the classification of cancer patients according to their tumors carry mutations and thus advance the implementation of the most appropriate individualized for each patient therapies.

"This award helps to give visibility to the Biomedical Research and lets the society know the people who do research. It is a social recognition of the work we do and it is an honor for me that the research done in my group has been recognized" said Núria when knowing the news."In Barcelona, high quality biomedicine research is made with leading research groups in this field to develop high-impact projects for society. For me, it is a luxury to do research in this environment and appear next to the remains of scientists who have been honored with this award".

More information

Albert Antolín and María Martí


Two doctoral students of GRIB awarded with the Doctoral School PhD Extraordinary Prize of the PhD Programme in Biomedicine of the UPF

Seven PhD Extraordinary Awards have been given of a total of 75 PhD theses defended in the academic year 2014-2015. Albert Antolín and Maria Martí have been awarded with this extraordinary Prize of the PhD Programme in Biomedicine.

The thesis of Albert Antolín, directed by Dr. Jordi Mestres, head of the Systems Pharmacology Group of GRIB, was entitled "The Impact of Polypharmacology on Chemical Biology" and focused on the selectivity of small molecules on their target proteins and its implications on pharmacological safety.

The thesis of Maria Martí, directed by Dr. Manuel Pastor and Dr. Jana Selent, head and PI respectively of the PharmacoInformatics group of GRIB, was entitled "Ligand selectivity at GPCRs: from multi-target binding profiles to biased agonism" and focused on the detection of molecules that enable the development of more efficient and secure antipsychotic drugs.

Albert Antolín is currently a Marie Curie Tecniospring postdoctoral fellow at the Hospital del Mar Medical Research Institute (IMIM) and María Martí is currently a postdoctoral fellow at the Institute of Pharmaceutical Chemistry of the Philipps University of Marburg, Germany. We congratulate both for this award!

The PhD Extraordinary Prizes will be officially presented at the UPF Graduation Ceremony for master's and doctoral degrees that will take place on July 1st, 2016, at the Ciutadella Campus. 

More information

DisGeNET discovery platform


A new version of DisGeNET has been released!!!!

DisGeNET is a discovery platform integrating information on gene-disease associations from several public data sources and the literature. Developed by the Integrative Biomedical Informatics group of GRIB, DisGeNET integrates expert-curated databases with text-mined data, and it is one of the largest available repositories of its kind. 

The new release of DisGeNET contains more than 400,000 gene-disease associations, comprising around 17,000 genes, and more than 15,000 diseases and phenotypes. Some of the new features of the current release include new expert-curated databases, information on more than 45,000 SNPs associated to diseases, new annotations of genes to phenotypes, the DisGeNET Gene-Disease association type ontology updated with new association types and new features to prioritize genes, and more...

For further details, visit the DisGeNET website and follow us at twitter @DisGeNET

More information


Project MedBioinformatics promotes the 1st European Conference on Translational Bioinformatics (ECTB 2016)

The conference took place at the University of Copenhagen on April 26-27, bringing together 150 experts in the area.

The conference addressed among others the following topics: Biomedical big data approaches, Data capture and curation, Precision medicine and Data integration and analytics combining omics and clinical data

ECTB is a new series of scientific conferences promoted by the MedBioinformatics project, which aims to have continuity by means of new editions to be held in UK (2017) and Barcelona (2018). 

MedBioinformatics "Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities" is a project funded by H2020 and coordinated by the GRIB with the participation of other research groups of IMIM and UPF.

For more information about the conference please visit:

More information

Allegoric representation of the variability of the transcriptome through changes in alternative splicing in difference cancer types. Illustration by Babita Singh


Scientists of GRIB find a new molecular mechanism involved in the development of cancer

Researchers of the Computational Genomics group of GRIB (UPF-IMIM) led by Eduardo Eyras, have discovered new alterations linked to cancer and have revealed the importance of the transcriptome in the development of tumours. For the first time, scientists have studied the variability of the cell transcriptome in several tumours at the same time, that is, not focusing on the DNA but on the products extracted from it. The results of the study have been published in the journal Genome Research.

Thanks to the bioinformatics tools developed by the research group, in record time and using limited computational resources, the scientists have been able to carry out a comprehensive analysis of the transcriptome of over 4,000 tumour samples from eleven different types of cancer taken from the TCGA project. This analysis shows that the proteins bound to the RNA are very often altered in human tumours and that these alterations determine the cell transcriptome and induce cell transformations related to the development of cancer. Until now, these alterations remained invisible to the methods used in major cancer genome analysis projects.

Reference work: Sebestyen E, Singh B, Miñana B, Pages A, Mateo F, Pujana MA, Valcarcel J, Eyras E. Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome Research, 2016.  DOI: 10.1101/ gr. 199935. 115

More information

Site Information